Physician profile
Gregory L Moore
NPI 1679889166
$4,287.48
in general payments reported to CMS, 2019-2025
27 companies · $16.31 in 2025
The $16.31 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $639 · 2022: $838 · 2023: $1,660 · 2024: $1,135 · 2025: $16.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,810.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,091.08 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,004.30 | 2021-2024 | Xifaxan, Trulance, Uceris |
| Janssen Biotech, INC. | $373.37 | 2021-2024 | Stelara, Remicade, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $289.00 | 2021-2024 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $283.38 | 2022-2024 | Dupixent |
| Merck Sharp & Dohme LLC | $213.42 | 2021-2023 | Dificid, Zinplava |
| Genzyme Corporation | $201.88 | 2022-2024 | |
| Ironwood Pharmaceuticals, INC | $131.61 | 2022-2024 | Linzess |
| Qol Medical, LLC | $125.72 | 2023-2024 | Sucraid, Sucraid |
| Ferring Pharmaceuticals INC. | $91.67 | 2022-2024 | Rebyota |
| Gilead Sciences, INC. | $76.10 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $65.55 | 2024 | Voquezna |
| Intercept Pharmaceuticals, INC. | $49.93 | 2021-2024 | |
| Pfizer INC. | $44.01 | 2021 | |
| Kci USA, INC. | $36.80 | 2023 | Prevena |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $27.49 | 2021-2022 | |
| Daiichi Sankyo INC. | $23.15 | 2022 | |
| Nestle Healthcare Nutrition INC. | $20.64 | 2021 | |
| Redhill Biopharma INC. | $20.32 | 2021 | |
| Braintree Laboratories, INC. | $17.07 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.34 | 2022 | |
| Lilly USA, LLC | $16.31 | 2025 | Mounjaro |
| Organon LLC | $15.45 | 2023 | Hadlima |
| La Jolla Pharmaceutical Company | $15.07 | 2023 | Xerava |
| Fresenius Kabi USA, LLC | $14.15 | 2023 | Idacio |
| Phadia US INC. | $13.49 | 2021 | |
| Vivus LLC | $10.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.